U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
RegulatoryapprovedCamzyosPositive
AI Analysis
Summary
Bristol Myers Squibb announced FDA approval of an expanded indication for Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in both adults and pediatric patients.
Outcome Details
FDA approved expanded indication for Camzyos (mavacamten) for treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients
Importance:8/10
Sentiment:
0.85
FDA approvalexpanded indicationcardiovascularpediatric indication
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 30, 2026 10:09 PM